What is more important is that previous studies mainly focused on the analysis of survival differences with a lack of comparison of recurrence pattern with HER2‐low and HER2‐zero breast cancer, such as the difference of metastatic sites and the difference of the recurrence time curves between HER2‐low and HER2‐zero. This evidence concerns the gene ERBB2 and breast carcinoma.